Previous 10 | Next 10 |
Deciphera Pharmaceuticals ( DCPH ) is a small company with a pipeline of small molecules targeting various causes of cancer. Lead candidate Ripretinib is an orally administered kinase switch control inhibitor being developed for the treatment of "gastrointestinal stromal tumors (GIST), advan...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
The following slide deck was published by Blueprint Medicines Corporation in conjunction with this Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen...
CAMBRIDGE, Mass. , March 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers , Blueprint Medicines' Chief Executive O...
The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q4 earnings Read more ...
Blueprint Medicines (BPMC) Q4 2018 Earnings Conference Call February 26, 2019 8:30 A.M. ET Company Participants Jim Baker - Vice President, Corporate Affairs Jeff Albers - Chief Executive Officer Kate Haviland - Chief Operating Officer Andy Boral - Chief Medical Officer Mike ...
Blueprint Medicines (NASDAQ: BPMC ): Q4 GAAP EPS of -$1.83 misses by $0.07 . More news on: Blueprint Medicines, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , Feb. 26, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth ...
CAMBRIDGE, Mass. , Feb. 19, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-07-29 07:15:06 ET Barclays analyst issues EQUAL-WEIGHT recommendation for BPMC on July 29, 2024 05:43AM ET. The previous analyst recommendation was Equal-Weight. BPMC was trading at $112.19 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $105.00 for BPMC on 2024-07-29 05:43:00. The adjusted price target was set to $105.00. At the time of the announcement, BPMC was trading at $112.19. The overall price target consensus is at $100.7...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...